AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects

NCT ID: NCT00995605

Last Updated: 2009-10-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-04-30
• Study Completion Date: 2009-08-31

Brief Summary

The purpose of this study is to determine whether AMAP102 is safe and well tolerated by humans.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Groups SAD

AMAP102 or Placebo as single ascending doses in five groups

Group Type: EXPERIMENTAL

AMAP102

Intervention Type: DRUG

AMAP102 or Placebo

Groups MAD

AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups

Group Type: EXPERIMENTAL

AMAP102

Intervention Type: DRUG

AMAP102 or Placebo

Interventions

AMAP102

AMAP102 or Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. In Groups A, B, D, E and F, subjects will be males of any ethnic origin between 18 and 65 years of with a BMI between 20.0 and 30.0 kg/m2

2. In Group C, subjects will be females (of non-childbearing potential) of any ethnic origin between 18 and 65 years with a BMI between 20.0 and 28.0 kg/m2

3. For Group C, women will be of non-childbearing potential, defined as surgically sterile or post-menopausal, non-lactating and having a negative serum pregnancy test

4. Subjects must be in good health, as determined by a medical history, physical examination, 12-lead ECG and clinical laboratory evaluations

5. Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions

Exclusion Criteria

1. Male subjects who are not willing to use appropriate contraception from the time of the first dose until 3 months after the final dosing occasion

2. Subjects who have received any prescribed systemic or topical medication within 14 days of the first dose administration

3. Subjects who have used any non-prescribed systemic or topical medication within 7 days of the first dose administration

4. Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration

5. Subjects who are still participating in a clinical study or who have participated in a clinical study involving administration of an investigational drug in the past 3 months

6. Subjects who have donated any blood, plasma or platelets in the month prior to screening or who have made donations on more than two occasions within the 12 months preceding the first dose administration

7. Subjects with a significant history of drug allergy as determined by the Investigator

8. Subjects who have any clinically significant allergic disease as determined by the Investigator

9. Subjects who have a supine blood pressure and supine pulse rate higher than 140/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/50 mmHg and 40 bpm, respectively

10. Subjects who consume more than 28 units (males) or more than 21 units (females) of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse as determined by the Investigator (one unit of alcohol equals ½ pint [285 mL] of beer or lager, one glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits)

11. Subjects who smoke more than 10 cigarettes or the equivalent in tobacco per day

12. Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorders as determined by the Investigator

13. Subjects who have had a clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator

14. Subjects who are known to have serum hepatitis, or who are carriers of the HBsAg or hepatitis C antibody, or who have a positive result to the test for HIV antibodies

15. Subjects who have an abnormality in the 12-lead ECG such that, in the opinion of the investigator, increases the risk of participating in the study, such as QTc(b) interval greater than 430 msec (male) or greater than 450 msec (female), 2nd or 3rd degree Atrioventricular block, complete left bundle branch block, complete right bundle branch block or Wolff-Parkinson-White Syndrome, defined as PR shorter than 110 msec, confirmed by a repeat ECG

16. Subjects with a significant cardiac history (e.g. heart failure, hypokalemia, long QT syndrome), significant history of fainting, syncope or family history of sudden cardiac death

17. Subjects who, in the opinion of the Investigator, should not participate in the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

AnaMar AB

INDUSTRY

Sponsor Role: lead

Principal Investigators

Dr Joseph Chiesa, MD FFPM FICR CSci

Role: PRINCIPAL_INVESTIGATOR

Covance

Locations

Covance Clinical Research Unit Ltd.

Leeds, , United Kingdom

Countries

United Kingdom

Other Identifiers

2008-004940-35

Identifier Type: -

Identifier Source: secondary_id

2704-026

Identifier Type: -

Identifier Source: secondary_id

102-240-01

Identifier Type: -

Identifier Source: org_study_id